Nonhematopoietic antigen blocks memory programming of alloreactive CD8 + T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation

Journal of Clinical Investigation

Volumn 120, Issue 11, 2010, Pages 3855-3868

  Flutter, Barry ^a   Edwards, Noha ^a   Fallah Arani, Farnaz ^a   Henderson, Stephen ^b   Chai, Jian Guo ^c   Sivakumaran, Shivajanani ^a   Ghorashian, Sara ^a   Bennett, Clare L ^a   Freeman, Gordon J ^d   Sykes, Megan ^e   Chakraverty, Ronjon ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d HARVARD MEDICAL SCHOOL   (United States)

^e NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 RECEPTOR;

ALLOIMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RELAPSE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNITY; IMMUNOSURVEILLANCE; LIGAND BINDING; LYMPHOCYTE FUNCTION; MEMORY CELL; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; TREATMENT FAILURE; TUMOR RECURRENCE;

ANIMALS; ANTIGENS; ANTIGENS, DIFFERENTIATION; BONE MARROW TRANSPLANTATION; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNOLOGIC MEMORY; MALE; MICE; MODELS, ANIMAL; TRANSPLANTATION CHIMERA;

EID: 78049443551     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI41446     Document Type: Article

References (75)

1. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103(3):767-776.
2. Sprangers B, Van Wijmeersch B, Fevery S, Waer M, Billiau AD. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect. Nat Clin Pract Oncol. 2007;4(7):404-414.
3. Chakraverty R, et al. An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med. 2006; 203(8):2021-2031. (Pubitemid 44188475)
4. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90(8):3204-3213. (Pubitemid 27444217)
5. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus- host disease in H-2-incompatible transplanted SCID mice. Blood. 1994;83(8):2360-2367.
6. Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG. Hostreactive CD8(+) memory stem cells in graft-versushost disease. Nat Med. 2005;11(12):1299-1305.
7. Billiau AD, Fevery S, Rutgeerts O, Landuyt W, Waer M. Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versushost and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants. Blood. 2002;100(5):1894-1902. (Pubitemid 34925171)
8. Johnson BD, Truitt RL. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versushost disease. Blood. 1995;85(11):3302-3312.
9. Sykes M, Bukhari Z, Sachs DH. Graft-versus-leukemia effect using mixed allogeneic bone marrow transplantation. Bone Marrow Transplant. 1989;4(5):465-474. (Pubitemid 19236576)
10. Peggs KS, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 2004;103(4):1548-1556.
11. Chakraverty R, et al. Host MHC class II+ antigenpresenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood. 2006;108(6):2106-2113. (Pubitemid 44395027)
12. Ghosh A, et al. Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graftversus-leukemia effects across MHC barriers in full chimeras. Blood. 2009;113(18):4440-4448.
13. Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood. 2002; 100(5):1903-1909. (Pubitemid 34925172)
14. Xia G, Truitt RL, Johnson BD. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Biol Blood Marrow Transplant. 2006;12(4):397-407.
15. Chakraverty R, et al. The host environment regulates the function of CD8+ graft-versus-host-reactive effector cells. J Immunol. 2008;181(10):6820-6828.
16. Durakovic N, et al. Factors governing the activation of adoptively transferred donor T-cells infused after allogeneic bone marrow transplantation in the mouse. Blood. 2007;109(10):4564-4574.
17. Mapara MY, Kim YM, Marx J, Sykes M. Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism. Transplantation. 2003;76(2):297-305.
18. Meunier MC, Baron C, Perreault C. Two host factors regulate persistence of H7-specific T cells injected in tumor-bearing mice. PLoS One. 2009;4(1):e4116.
19. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol. 2006;24:175-208.
20. Shin H, Wherry EJ. CD8 T cell dysfunction during chronic viral infection. Curr Opin Immunol. 2007;19(4):408-415. (Pubitemid 47284857)
21. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol. 2003;77(8):4911-4927. (Pubitemid 36402840)
22. Barber DL, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682-687. (Pubitemid 43237609)
23. van Rhee F, et al. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant. 1998;21(10):1055-1061.
24. Yamamoto R, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 2008; 111(6):3220-3224.
25. Kaech SM, Wherry EJ. Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. Immunity. 2007;27(3):393-405.
26. Bannard O, Kraman M, Fearon DT. Secondary replicative function of CD8+ T cells that had developed an effector phenotype. Science. 2009; 323(5913):505-509.
27. Joshi NS, et al. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity. 2007;27(2):281-295.
28. Sarkar S, Kalia V, Haining WN, Konieczny BT, Subramaniam S, Ahmed R. Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates. J Exp Med. 2008;205(3):625-640. (Pubitemid 351439309)
29. Mueller SN, Ahmed R. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A. 2009; 106(21):8623-8628.
30. Golden-Mason L, Palmer B, Klarquist J, Mengshol JA, Castelblanco N, Rosen HR. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol. 2007; 81(17):9249-9258. (Pubitemid 47311467)
31. Katou F, Ohtani H, Watanabe Y, Nakayama T, Yoshie O, Hashimoto K. Differing phenotypes between intraepithelial and stromal lymphocytes in early-stage tongue cancer. Cancer Res. 2007;67(23):11195-11201. (Pubitemid 350248544)
32. Keir ME, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006; 203(4):883-895.
33. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol. 2001;19:47-64.
34. Kean LS, et al. NK cells mediate costimulation blockade-resistant rejection of allogeneic stem cells during nonmyeloablative transplantation. Am J Transplant. 2006;6(2):292-304. (Pubitemid 43382164)
35. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745-763. (Pubitemid 38680440)
36. Sha WC, Nelson CA, Newberry RD, Kranz DM, Russell JH, Loh DY. Positive and negative selection of an antigen receptor on T cells in transgenic mice. Nature. 1988;336(6194):73-76.
37. Speir JA, et al. Structural basis of 2C TCR allorecognition of H-2Ld peptide complexes. Immunity. 1998; 8(5):553-562.
38. Billiau AD, Fevery S, Rutgeerts O, Landuyt W, Waer M. Transient expansion of Mac1+Ly6-G+ Ly6-C+ early myeloid cells with suppressor activity in spleens of murine radiation marrow chimeras: possible implications for the graft-versus-host and graft-versus-leukemia reactivity of donor lymphocyte infusions. Blood. 2003;102(2):740-748. (Pubitemid 36842001)
39. Krause DS, Van Etten RA. Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemialike myeloproliferative disease in a murine model. Blood. 2004;104(13):4236-4244.
40. Valujskikh A, Lantz O, Celli S, Matzinger P, Heeger PS. Cross-primed CD8(+) T cells mediate graft rejection via a distinct effector pathway. Nat Immunol. 2002;3(9):844-851.
41. Blackburn SD, Shin H, Freeman GJ, Wherry EJ. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A. 2008;105(39):15016-15021.
42. Blazar BR, et al. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. J Immunol. 2000;165(9):4901-4909.
43. Laouar A, Manocha M, Haridas V, Manjunath N. Concurrent generation of effector and central memory CD8 T cells during vaccinia virus infection. PLoS One. 2008;3(12):e4089.
44. Obar JJ, Lefrancois L. Early signals during CD8(+) T cell priming regulate the generation of central memory cells. J Immunol. 2010;185(1):263-272.
45. Li Q, et al. Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection. Science. 2009;323(5922):1726-1729.
46. Rocha B, Grandien A, Freitas AA. Anergy and exhaustion are independent mechanisms of peripheral T cell tolerance. J Exp Med. 1995;181(3):993-1003.
47. Scholer A, Hugues S, Boissonnas A, Fetler L, Amigorena S. Intercellular adhesion molecule-1- dependent stable interactions between T cells and dendritic cells determine CD8+ T cell memory. Immunity. 2008;28(2):258-270.
48. Marzo AL, Klonowski KD, Le Bon A, Borrow P, Tough DF, Lefrancois L. Initial T cell frequency dictates memory CD8+ T cell lineage commitment. Nat Immunol. 2005;6(8):793-799.
49. Teixeiro E, et al. Different T cell receptor signals determine CD8+ memory versus effector development. Science. 2009;323(5913):502-505.
50. Rutishauser RL, et al. Transcriptional repressor Blimp-1 promotes CD8(+) T cell terminal differentiation and represses the acquisition of central memory T cell properties. Immunity. 2009;31(2):296-308.
51. Gattinoni L, et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med. 2009;15(7):808-813.
52. Araki K, et al. mTOR regulates memory CD8 T-cell differentiation. Nature. 2009;460(7251):108-112.
53. Redmond WL, Sherman LA. Peripheral tolerance of CD8 T lymphocytes. Immunity. 2005;22(3):275-284.
54. Wherry EJ, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007;27(4):670-684.
55. Kawase T, et al. HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood. 2009; 113(12):2851-2858.
56. Rutten CE, et al. HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia. Leukemia. 2008;22(7):1387-1394.
57. Dodero A, et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood. 2009;113(19):4771-4779.
58. Ferber I, Schonrich G, Schenkel J, Mellor AL, Hammerling GJ, Arnold B. Levels of peripheral T cell tolerance induced by different doses of tolerogen. Science. 1994;263(5147):674-676.
59. Kloosterboer FM, et al. Direct cloning of leukemiareactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. Leukemia. 2004;18(4):798-808.
60. Malarkannan S, et al. The molecular and functional characterization of a dominant minor H antigen, H60. J Immunol. 1998;161(7):3501-3509.
61. Beatty GL, et al. Functional unresponsiveness and replicative senescence of myeloid leukemia antigenspecific CD8+ T cells after allogeneic stem cell transplantation. Clin Cancer Res. 2009;15(15):4944-4953.
62. Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease. J Immunol. 2005;174(5):3051-3058. (Pubitemid 40279726)
63. Blaser BW, et al. Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity. Blood. 2006;108(7):2463-2469.
64. Kosaka H, Sprent J. Tolerance of CD8+ T cells developing in parent - >F1 chimeras prepared with supralethal irradiation: step-wise induction of tolerance in the intrathymic and extrathymic environments. J Exp Med. 1993;177(2):367-378.
65. Lee JW, et al. Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self. Nat Immunol. 2007;8(2):181-190.
66. Mueller SN, Ahmed R. Lymphoid stroma in the initiation and control of immune responses. Immunol Rev. 2008;224:284-294.
67. Davenport MP, Belz GT, Ribeiro RM. The race between infection and immunity: how do pathogens set the pace? Trends Immunol. 2009;30(2):61-66.
68. Mueller SN, et al. Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proc Natl Acad Sci U S A. 2007;104(39):15430-15435.
69. Asakura S, et al. Alloantigen expression on nonhematopoietic cells reduces graft-versus-leukemia effects in mice. J Clin Invest. 2010;120(7):2370-2378.
70. Mueller SN, et al. PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice. J Clin Invest. 2010;120(7):2508-2515.
71. Shlomchik WD, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285(5426):412-415.
72. Teshima T, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med. 2002;8(6):575-581.
73. Rodig N, et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol. 2003;33(11):3117-3126.
74. Zang W, et al. Inhibition of the alloimmune response through the generation of regulatory T cells by a MHC class II-derived peptide. J Immunol. 2008; 181(11):7499-7506.
75. Sykes M, Szot GL, Swenson KA, Pearson DA. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med. 1997; 3(7):783-787.